Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer …

Articles citing Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer …

Title / Author	Year
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden ZR Chalmers, CF Connelly, D Fabrizio, L Gay, SM Ali, R Ennis, A Schrock, ... Genome medicine 9 (1), 34	2017
Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers AM Goodman, S Kato, L Bazhenova, SP Patel, GM Frampton, V Miller, ... Molecular cancer therapeutics 16 (11), 2598-2608	2017
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response AC Huang, MA Postow, RJ Orlowski, R Mick, B Bengsch, S Manne, W Xu, ... Nature 545 (7652), 60	2017
PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome HO Alsaab, S Sau, R Alzhrani, K Tatiparti, K Bhise, SK Kashaw, AK Iyer Frontiers in pharmacology 8, 561	2017
Tumor and microenvironment evolution during immunotherapy with nivolumab N Riaz, JJ Havel, V Makarov, A Desrichard, WJ Urba, JS Sims, FS Hodi, ... Cell 171 (4), 934-949. e16	2017
Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing C Zheng, L Zheng, JK Yoo, H Guo, Y Zhang, X Guo, B Kang, R Hu, ... Cell 169 (7), 1342-1356. e16	2017
Evolution of neoantigen landscape during immune checkpoint blockade in non–small cell lung cancer V Anagnostou, KN Smith, PM Forde, N Niknafs, R Bhattacharya, J White, ... Cancer discovery 7 (3), 264-276	2017
Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy S Spranger, D Dai, B Horton, TF Gajewski Cancer cell 31 (5), 711-723. e4	2017
Biomarker development in the precision medicine era: lung cancer as a case study AJ Vargas, CC Harris Nature Reviews Cancer 16 (8), 525	2016
Comprehensive analysis of hypermutation in human cancer BB Campbell, N Light, D Fabrizio, M Zatzman, F Fuligni, R de Borja, ... Cell 171 (5), 1042-1056. e10	2017
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response G Chen, AC Huang, W Zhang, G Zhang, M Wu, W Xu, Z Yu, J Yang, ... Nature 560 (7718), 382	2018
Near-infrared-triggered photodynamic therapy with multitasking upconversion nanoparticles in combination with checkpoint blockade for immunotherapy of colorectal cancer J Xu, L Xu, C Wang, R Yang, Q Zhuang, X Han, Z Dong, W Zhu, R Peng, ... ACS nano 11 (5), 4463-4474	2017
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy D Chowell, LGT Morris, CM Grigg, JK Weber, RM Samstein, V Makarov, ... Science 359 (6375), 582-587	2018
Precision diagnosis and treatment for advanced non–small-cell lung cancer M Reck, KF Rabe New England Journal of Medicine 377 (9), 849-861	2017
Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma ZY Dong, WZ Zhong, XC Zhang, J Su, Z Xie, SY Liu, HY Tu, HJ Chen, ... Clinical cancer research 23 (12), 3012-3024	2017
Recent progress on semiconducting polymer nanoparticles for molecular imaging and cancer phototherapy J Li, J Rao, K Pu Biomaterials 155, 217-235	2018
Assessing tumor infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (6), 311	2017
Fibroblast heterogeneity and immunosuppressive environment in human breast cancer A Costa, Y Kieffer, A Scholer-Dahirel, F Pelon, B Bourachot, M Cardon, ... Cancer Cell 33 (3), 463-479. e10	2018
Photodynamic therapy mediated by nontoxic core–shell nanoparticles synergizes with immune checkpoint blockade to elicit antitumor immunity and antimetastatic effect on breast cancer X Duan, C Chan, N Guo, W Han, RR Weichselbaum, W Lin Journal of the American Chemical Society 138 (51), 16686-16695	2016
Biomarkers of response to PD-1/PD-L1 inhibition SM Vareki, C Garrigos, I Duran Critical reviews in oncology/hematology 116, 116-124	2017

1 - 20

Dates and citation counts are estimated and are determined automatically by a computer program.